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Systemic anticancer treatments fail in a substantial number of patients. This may be
caused by inadequate uptake and penetration of drugs in malignant tumors. Consequently,
improvement of drug delivery to solid tumors may enhance its efficacy. Before evaluat-
ing strategies to enhance drug uptake in tumors, better understanding of drug delivery to
human tumors is needed. Positron emission tomography (PET) is an imaging technique
that can be used to monitor drug pharmacokinetics non-invasively in patients, based on
radiolabeling these drugs with short-lived positron emitters. In this mini review, principles
and potential applications of PET using radiolabeled anticancer drugs will be discussed with
respect to personalized treatment planning in oncology. In particular, it will be discussed
how these radiolabeled anticancer drugs could help to develop strategies for improved
drug delivery to solid tumors. The development and clinical implementation of PET using
radiolabeled anticancer drugs will be illustrated by validation studies of carbon-11 labeled
docetaxel ([11C]docetaxel) in lung cancer patients.
Keywords: positron emission tomography, radiolabeled anticancer drugs, drug delivery, tumors, [11C]docetaxel,
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INTRODUCTION
To date, an increasing number of anticancer drugs is available
for treating cancer patients. Nevertheless, resistance to anticancer
drugs remains a problem in a substantial number of patients and,
consequently, these patients may suffer from drug-induced tox-
icities without any benefit. Tumor response to anticancer drugs
is, amongst others, thought to be directly related to drug con-
centrations in tumor tissue. Strategies that improve drug delivery
to tumors may therefore enhance efficacy of anticancer drugs.
Prior to the evaluation of these strategies, better understand-
ing of drug delivery to human tumors is needed. Direct assess-
ment of tumor drug concentrations in cancer patients, how-
ever, is challenging, as it requires accessibility to tumors that
are usually deeply seated within the body. Positron emission
tomography (PET) is an imaging technique that can be used
to monitor drug pharmacokinetics non-invasively in patients by
radiolabeling drugs of interest with short-lived positron emit-
ters. In this mini review, principles and potential applications
of PET using radiolabeled anticancer drugs will be discussed
for personalized treatment planning in oncology. Furthermore,
development and clinical implementation of radiolabeled anti-
cancer drugs will be illustrated by validation studies of carbon-
11 labeled docetaxel ([11C]docetaxel) in lung cancer patients.
Finally, it will be discussed how these radiolabeled anticancer drugs
could help to develop strategies for improved drug delivery to
tumors.
POSITRON EMISSION TOMOGRAPHY
PRINCIPLES OF PET
Positron emission tomography is a highly sensitive nuclear imag-
ing technique that enables non-invasive in vivo monitoring of
dynamic processes (1). PET tracers are molecules of interest that
are labeled with a positron emitting radionuclide. Such a radionu-
clide decays by emission of a positron from its nucleus, which
almost immediately results in the simultaneous emission of two
gamma rays in opposite direction. For PET imaging, in general
short-lived radionuclides, such as carbon-11 [11C], fluorine-18
[18F], and oxygen-15 [15O] are used. A PET scanner usually con-
sists of a ring of detectors and is capable of detecting high-energy
gamma rays that are emitted from tissue after intravenous admin-
istration of a PET tracer (Figure 1). After reconstruction, data
obtained provide information on the 3-dimensional tracer con-
centration within the body. To date, a PET scanner is combined
with an integrated computed tomography (CT) scanner (2), which
is used for attenuation correction as well as anatomical localization
of tracer uptake.
KINETIC MODELING OF PET DATA
In clinical practice, a PET image can be extremely useful for diag-
nosis and staging of cancer. However, absolute quantification of
tracer kinetics in tissue is necessary for complete characteriza-
tion of functional processes in vivo. For quantification of tracers,
their uptake in tissue needs to be measured as function of time.
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FIGURE 1 | Schematic illustration of an annihilation reaction and the
subsequent coincidence detection. Positrons released from the nucleus
of the radionuclide annihilate with electrons in tissue, releasing two
coincidence photons of 511 keV, which are detected by scintillation crystals
(blue rectangles). Coincidence detection of annihilated photons identifies a
line-of-response and makes it possible to localize the source of the
annihilation.
Therefore, PET data need to be acquired as dynamic rather than
static scans. For diagnostic purposes, usually whole body scans
are performed, which consist of a series of static scans by moving
the scanner bed over multiple bed positions. During a dynamic
PET scan, patients are scanned at one bed position and detailed
(kinetic) information on a selected part of the body is obtained.
As a result, a dynamic scan is limited by the field of view of the
PET scanner, which is ∼15–20 cm. Consequently, the tissue of
interest needs to be adequately defined prior to acquisition of the
PET data. Net tracer uptake in tissue is determined by its deliv-
ery, extraction from blood and washout from tissue as function of
time. Each tracer has its own distinct behavior in vivo, which can
be described by tracer kinetic models (3). Several compartmental
models have been developed to describe PET data. In Figure 2,
schematic diagrams of standard single tissue and two tissue com-
partment models are presented. The kinetic rate constants in these
models can be estimated from dynamic PET data. To this end, a tis-
sue time-activity curve (TAC; Figure 3) is fitted to the appropriate
model equation using the arterial plasma TAC as input function,
and the best fit then provides estimates of these kinetic parameters
(Figure 4). The arterial input function can be obtained from arte-
rial blood sampling using an on-line detection system (4). Arterial
blood sampling, however, is an invasive and cumbersome proce-
dure. In principle, the time course of the tracer in a large arterial
blood structure, e.g., the aorta, can also be used to generate a
non-invasive image derived input function.
PET IMAGING IN ONCOLOGY
Over the past decade, clinical applications of PET have expanded,
particularly in oncology. To date, 2-deoxy-2-[18F]fluoro-d-
glucose ([18F]FDG) is the most widely used PET tracer for eval-
uation of cancer. High [18F]FDG uptake in tumors is based
on altered glucose metabolism in most cancer cells (5). As
[18F]FDG uptake in tissue is not specific for malignancy and
does not provide information on other biological characteristics
of tumors, other PET tracers have been developed. For example,
3-deoxy-3-[18F]fluorothymidine ([18F]FLT) has been developed
FIGURE 2 | Compartment models to describe the behavior of a tracer
in tissue. (A) Schematic diagram of a single tissue compartment model in
which only one tissue compartment can be distinguished, such as in the
case of a flow tracer. According to this model, the tracer concentration in
tissue (CTissue) depends on plasma concentration (CPlasma), influx from plasma
(K 1 or rate constant for transfer from plasma to tissue), and clearance from
tissue to plasma (k 2 or rate constant for transfer from tissue to plasma). (B)
Schematic diagram of a two tissue compartment model. CTissue consists of
tracer concentrations in compartments 1 and 2, representing free (C1) and
bound or metabolized tracer (C2), respectively. Tracer kinetics in tissue are
regulated by CPlasma and four kinetic rate constants K 1, k 2, k 3, and k 4. K 1 is
the rate constant for transport from plasma to tissue, k 2 for transport from
tissue to plasma, and k 3 and k 4 are kinetic rate constants describing
exchange between the two tissue compartments. For an irreversible two
tissue compartment model k 4 =0.
FIGURE 3 |Time-activity curves. Example of time-activity curves of
radioactivity concentrations in plasma and two different tissues of interest.
to measure tumor proliferation (6). In addition, radioactive water
([15O]H2O) can be used to measure tumor perfusion (7), whereas
hypoxia tracers such as [18F]fluoroazomycinarabinofuranoside
([18F]FAZA) and [18F]fluoromisonidazole ([18F]FMISO) can
be used to determine hypoxic areas in tumors (8). Although
these PET tracers may provide additional information on var-
ious biological processes in tumors and could be useful for
response evaluation, they are not specific enough to predict tumor
response to specific anticancer drugs. As an alternative, anti-
cancer drugs can be labeled with positron emitters. Using PET,
these radiolabeled drugs can then be used to monitor drug phar-
macokinetics in patients non-invasively. As tumor response to
Frontiers in Oncology | Pharmacology of Anti-Cancer Drugs August 2013 | Volume 3 | Article 208 | 2
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van der Veldt et al. PET using radiolabeled anticancer drugs
FIGURE 4 | Schematic diagram of data required for analysis of PET
data (TAC: time-activity curve).
anticancer drugs is thought to be directly related to drug con-
centrations in tumor tissue, uptake of radiolabeled anticancer
drugs in tumors may predict treatment outcome. Preliminary
PET studies using F-18 labeled 5-fluorouracil ([18F]5-FU; (9, 10)),
tamoxifen ([18F]fluorotamoxifen; (11)), and C-11 labeled doc-
etaxel ([11C]docetaxel; (12)) showed that high tumor uptake of the
radiolabeled anticancer drug was associated with improved tumor
response following corresponding therapy. These studies suggest
that radiolabeled anticancer drugs may be useful for prediction of
outcome prior to start of treatment. Consequently, an increasing
number of anticancer drugs has now been radiolabeled including
radiolabeled cytotoxic agents (e.g., [11C]temozolomide, [18F]5-
fluorouracil, and [11C]docetaxel), selective hormone recep-
tor modulators (e.g., [18F]fluorotamoxifen), tyrosine kinase
inhibitors (TKIs, e.g., N-[11C]methylimatinib, [11C]sorafenib,
and [11C]erlotinib), and monoclonal antibodies [Mabs, e.g.,
[89Zr]cetuximab, [89Zr]trastuzumab, and [89Zr]bevacizumab;
(10, 11, 13–20)].
DEVELOPMENT OF RADIOLABELED ANTICANCER DRUGS
For the development of radiolabeled anticancer drugs, a com-
plex, and expensive research infrastructure is required: a cyclotron
for production of positron emitters, an on-site good manufac-
turing practice laboratory for synthesis of the tracer, a PET/CT
scanner for acquisition of images, an on-line blood sampler in
case of arterial blood sampling, an on-site laboratory for measure-
ments of radioactivity concentrations and radioactive metabolites
in plasma, and dedicated computers and software to analyze and
quantify acquired PET data. In addition, these facilities need to
be staffed by qualified personnel including a cyclotron operator,
a chemist who synthesizes the PET tracer, a radiopharmacist who
is responsible for quality control of the tracer production, a tech-
nologist for acquiring PET images, a (nuclear medicine) physician
who is clinically responsible for the patient as well as for arterial
blood sampling, a chemist for analyzing blood samples during PET
scanning, and a physicist who is responsible for acquisition pro-
tocols and data analyses. The short half-lives of most PET tracers
require that these facilities and personnel are located and working
in the same building at very close proximity. Besides these logistic
issues, the use of PET and radiolabeled anticancer drugs can be
limited by technical issues including complex tracer synthesis and
the spatial resolution of the scanner. Before implementation of a
new PET tracer in the clinic, technical, and biological validation of
the tracer is required. To this end, the optimal patient population
should be selected based on patient characteristics and technical
issues.
THE EXAMPLE OF [11C]DOCETAXEL PET IN LUNG CANCER
PATIENTS
DOCETAXEL
The cytotoxic agent docetaxel is a taxane, a class of drugs consist-
ing of microtubule stabilizing agents that function primarily by
interfering with microtubular dynamics, inducing cell cycle arrest
and apoptosis (21). In clinical practice, docetaxel is administered
as a 1-h intravenous infusion, usually given at a dose of 75 or
100 mg m−2 in a three-weekly regimen. In 1996, docetaxel was first
approved for the treatment of anthracycline-refractory metastatic
breast cancer. Thereafter, the drug was registered as monotherapy
as well as in combination strategies for the treatment of several
advanced malignancies including hormone refractory metastatic
prostate cancer, gastric adenocarcinoma, head and neck cancer,
and non-small cell lung cancer (NSCLC) (21). In these malig-
nancies, docetaxel has shown clinical efficacy, including tumor
response and improved survival. Nevertheless, failure of docetaxel
therapy occurs and patients are often subjected to docetaxel related
toxicities without gaining benefit.
LABELING OF DOCETAXEL
Docetaxel has been radiolabeled with the radionuclide carbon-
11 (22, 23). As a stable carbon atom is replaced by carbon-11
(Figure 5), the chemical structure of the tracer [11C]docetaxel
is identical to that of the drug docetaxel. Hence, pharmacoki-
netics of tracer and drug are identical. As the specific activity
of [11C]docetaxel is approximately 10 GBqµmol−1, which con-
tains 30µg docetaxel for a typical administration of 370 MBq
[11C]docetaxel, only 0.02% of a therapeutic dose of docetaxel
is administered for PET. As a result, [11C]docetaxel microdosing
prevents patients from drug-induced toxicities that are associated
with therapeutic doses. The following paragraphs describe succes-
sive steps in the validation of [11C]docetaxel for use in lung cancer
patients.
BIODISTRIBUTION OF [11C]DOCETAXEL IN RATS
In preparation of humans studies, the biodistribution of
[11C]docetaxel in healthy rats was investigated (24). This preclin-
ical study was needed to obtain an initial estimate of the expected
radiation dose in humans, which in turn was required for obtain-
ing ethics permission to conduct human studies. The biodistrib-
ution of [11C]docetaxel was determined in healthy male rats at 5,
15, 30, and 60 min after injection. This preclinical study showed
the highest [11C]docetaxel uptake in spleen, followed by urine,
lung and liver, whereas brain and testes showed the lowest uptake
(Figure 6). Within less than 5 min, [11C]docetaxel essentially had
cleared from blood and plasma. As the estimated effective dose in
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FIGURE 5 | Synthesis of [11C]docetaxel. [11C]docetaxel is synthesized by replacing a stable carbon atom by carbon-11 (22, 23), so that chemical properties of
stable and labeled compound are exactly the same.
FIGURE 6 | Biodistribution of [11C]docetaxel in healthy male rats. (A)
PET image showing the biodistribution of [11C]docetaxel in a male rat. This
image was obtained using a high resolution research tomograph (HRRT)
with a spatial resolution of about 2.5 mm. Red indicates the highest
[11C]docetaxel uptake. (B) Standardized uptake values of [11C]docetaxel in
organs as obtained from dissection studies. Standardized uptake values
were calculated as tissue radioactivity concentration normalized for
injected dose and body weight.
humans extrapolated from this rat study was 5.4µSv MBq−1, the
use of [11C]docetaxel in humans was considered to be safe.
BIODISTRIBUTION OF [11C]DOCETAXEL IN HUMANS
Following the preclinical study in rats, both biodistribution
and actual human radiation dosimetry of [11C]docetaxel was
determined in seven patients with solid tumors using whole
body PET/CT scans (25). Gall bladder and liver showed high
[11C]docetaxel uptake, whilst uptake in brain and normal lung
was low (Figure 7). In the liver, the percentage injected dose at
1 h was 47± 9%. In addition, [11C]docetaxel was rapidly cleared
from plasma and no radiolabeled metabolites were detected. The
effective dose of [11C]docetaxel was 4.7µSv MBq−1, which was
comparable to the estimated effective dose in rats. In contrast to
the preclinical study in rats, [11C]docetaxel showed low uptake in
human lungs. As a result, [11C]docetaxel could be a useful tracer
for tumors in the thoracic region.
QUANTIFICATION OF TUMOR UPTAKE
Although uptake of [11C]docetaxel in normal tissues may be
interesting, its uptake in tumor tissue is more important. The
feasibility of quantitative [11C]docetaxel PET scans was evalu-
ated in patients with lung cancer (Figure 8). In addition, it was
investigated whether [11C]docetaxel kinetics were associated with
tumor perfusion or tumor size. In this study, 34 lung cancer
patients underwent dynamic PET/CT scans using [11C]docetaxel
and [15O]H2O (12). For quantification of [11C]docetaxel kinetics,
the optimal tracer kinetic model was determined. Tumor kinetics
of [11C]docetaxel were irreversible and could be quantified using
Patlak graphical analysis. Furthermore, it was shown that repro-
ducible quantification of [11C]docetaxel kinetics in tumors was
possible using a non-invasive image derived input function. In
tumors, the net rate of influx (K i) of [11C]docetaxel was variable
and strongly related to tumor perfusion, but not to tumor size.
Finally, effects of dexamethasone administration on drug uptake
in tumors were investigated, as corticosteroids are potent induc-
ers of the drug efflux transporter ABCB1. Prior to administration
of therapeutic doses of docetaxel, all patients are premedicated
with corticosteroids, as this reduces incidence and severity of
docetaxel induced fluid retention and hypersensitivity reactions
significantly (26, 27). In this dynamic PET study, the first 24
patients were premedicated with dexamethasone, whereas the last
10 patients were not. In dexamethasone premedicated patients,
uptake of [11C]docetaxel in tumors was significantly lower than
in patients without premedication, indicating that co-medication
may affect accumulation of drugs in tumor tissue. Finally, in a
subgroup of patients who subsequently received docetaxel therapy,
high tumor uptake of [11C]docetaxel was related with improved
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FIGURE 7 | Biodistribution of [11C]docetaxel in patients. Four successive [11C]docetaxel whole body PET scans showing that [11C]docetaxel first accumulates
in liver, before being excreted into bile and ultimately into intestine. Because of high [11C]docetaxel uptake in the liver, these projections do not show the high
uptake of [11C]docetaxel in the gall bladder (25).
FIGURE 8 | (A) Summed PET image of [11C]docetaxel uptake from 10 to 60 min post injection showing a mediastinal metastasis with increased uptake [arrow;
(12)]. (B) Corresponding CT image. (C) PET-CT fusion image.
tumor response (12, 28), suggesting that the observed variation
in [11C]docetaxel kinetics between tumors may reflect differential
sensitivity to docetaxel therapy.
VALIDATION OF THE MICRODOSING CONCEPT
[11C]docetaxel microdosing protects patients from toxicities that
are associated with therapeutic doses of docetaxel. However, phar-
macokinetics of [11C]docetaxel at tracer doses may be different
from those at therapeutic doses, as the latter can significantly affect
uptake of radiolabeled anticancer drugs in normal organs as well
as in tumors (29–32). Therefore, the microdosing concept was val-
idated for [11C]docetaxel in another study (28). The research ques-
tion to be addressed was whether a PET study using a tracer dose of
[11C]docetaxel could predict tumor uptake of unlabeled docetaxel
during a therapeutic infusion. For this purpose, docetaxel naïve
lung cancer patients underwent two [11C]docetaxel PET scans, one
after a bolus injection of a tracer dose [11C]docetaxel and another
during a combined infusion of a tracer dose [11C]docetaxel and
a therapeutic dose of docetaxel (75 mg m−2). Compartmental
and spectral analyses were used to quantify [11C]docetaxel tumor
kinetics. In addition, [11C]docetaxel PET measurements were used
to estimate the area under the curve of therapeutic doses of doc-
etaxel in tumors. At 90 min, the accumulated amount of docetaxel
in tumors was<1% of the total infused dose of docetaxel, indicat-
ing that only a small amount accumulates in tumors. In addition,
the uptake of therapeutic doses in tumors was related to the
uptake of [11C]docetaxel during the microdosing scan, indicat-
ing that [11C]docetaxel PET can be used to predict tumor uptake
of docetaxel during chemotherapy.
COMBINATION THERAPY
Within the context of combination therapy, effects of the
anti-angiogenic drug bevacizumab on tumor perfusion and
[11C]docetaxel uptake in lung tumors were investigated in NSCLC
patients (33). Bevacizumab is a humanized monoclonal anti-
body that targets circulating vascular endothelial growth fac-
tor (VEGF) and subsequently prevents binding of VEGF to its
receptors. Combined with chemotherapy, bevacizumab has been
approved for the treatment of several advanced malignancies
including NSCLC (34). It is assumed that anti-angiogenic drugs,
www.frontiersin.org August 2013 | Volume 3 | Article 208 | 5
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
van der Veldt et al. PET using radiolabeled anticancer drugs
such as bevacizumab, transiently normalize abnormal tumor
vasculature and contribute to improved delivery of subsequent
chemotherapy (35). To investigate this concept, a study was per-
formed in NSCLC patients using PET and [11C]docetaxel. Within
5 h, a therapeutic dose of bevacizumab reduced both perfusion
and [11C]docetaxel uptake in NSCLC. These effects persisted
after 4 days and were not associated with significant changes in
heterogeneity of [11C]docetaxel uptake in tumors. Reduction in
[11C]docetaxel delivery to tumors was accompanied by rapid
reduction in circulating levels of VEGF. The clinical relevance of
these findings is notable (36–38), as there was no evidence for
substantial improvement in drug delivery to tumors after admin-
istration of bevacizumab. This study highlights the ability of PET
to potentially optimize scheduling of (anti-angiogenic) drugs.
CONCLUSION
PET using radiolabeled anticancer drugs may help to reveal the
underlying mechanisms of treatment failure in cancer patients. In
particular, this technology enables assessment of accumulation of
drugs in human tumors and, in turn, prediction of treatment out-
come. However, development of radiolabeled drugs faces several
caveats on the path from development to clinical implementa-
tion, as it can be very challenging due to technical, logistical,
financial, and/or patient related issues. To facilitate clinical imple-
mentation of radiolabeled drugs, a step-wise approach needs to be
applied. In this regard, the step-wise validation of [11C]docetaxel
in lung cancer patients provides a framework for investigating
the PET microdosing concept for other radiolabeled anticancer
drugs. The [11C]docetaxel PET studies have shown that only a
small amount of docetaxel accumulates in tumor tissue, which is
further decreased by co-medication (dexamethasone) and other
anticancer drugs (bevacizumab). In addition, it is conceivable that
drug delivery to tumors is also dependent on the localization of
tumors in de body, as drug delivery may differ between organs (e.g.,
brain versus liver). In this way, PET using radiolabeled anticancer
drugs may provide insight into drug delivery to human tumors
and may facilitate rational treatment choices that are tailored to
improve drug delivery to tumors.
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